头颈部癌症(HNC)的治疗通常基于单一或多模式疗法，包括手术、放疗(RT)、化疗和免疫治疗。然而，由于技术/人力资源和常规的本地实践的差异，不同国家之间的治疗建议可能存在差异。本综述旨在全球范围内识别、比较和绘制治疗口腔腺样细胞癌(SCC)、口咽、喉癌临床实践指南(CPG)。使用五个电子数据库和灰色文献进行头颈部癌症全球CPG的搜索策略。使用EndNote-20和Rayyan在线软件选择包含的CPG。没有语言或出版日期限制。结果进行描述性分析，考虑CPG的最新版本。总共找到了25个涵盖头颈部区域(10个)、喉部(7个)、口腔(5个)和口咽(3个)的CPG，涉及13个地理区域，其中19个由医学协会于1996年至2023年间制定。手术和放疗仍是早期HNC的主要模式，手术在低资源国家更常见，放疗在特定情况下，尤其是在喉部/口咽部可以保留器官的情况下，旨在实现根治。亚洲一些国家不检测口咽癌的人乳头瘤病毒感染，对于p16阳性和p16阴性病例的处理仍没有达成共识。关于保留喉部的建议因各国设施而异，但强调个体化选择。不同国家/大陆之间存在明显的不平等，具有相似的建议模式，无论是发达国家还是发展中国家。在拉丁美洲和大洋洲国家没有找到CPG，这些地区头颈部癌症的发病率较高，并且可能存在接受治疗的限制。

Head and neck cancer (HNC) treatments have been based on single or multimodal therapies with surgery, radiotherapy (RT), chemotherapy, and immunotherapy. However, treatment recommendations among countries may differ due to technological/human resources and usual local practices. This scoping review aims to identify, compare, and map the clinical practice guidelines (CPGs) for treating squamous cell carcinoma (SCC) of the oral cavity, oropharynx, and larynx worldwide. A search strategy on global CPGs for HNC was performed by using five electronic databases and grey literature. CPGs were selected for inclusion using EndNote-20 and Rayyan online software. No language or publication date restrictions were applied. The results were analyzed descriptively considering the most updated CPG version. In total, 25 CPGs covering the head and neck region (10), the larynx (7), the oral cavity (5), and the oropharynx (3), were found in 13 geographical regions, and 19 were developed by medical societies from 1996 to 2023. Surgery and RT remain the main modalities for early-stage HNC, with surgery preferred in low-resource countries, and RT in selected cases, especially in the larynx/oropharynx aiming to achieve a cure with organ preservation. Human papillomavirus infection for oropharyngeal SCC is not tested in some Asian countries and there is still no consensus to treat p16-positive cases differently from p16-negative. Recommendations for larynx preservation vary according to facilities in each country, however, individualized choice is emphasized. Inequality across countries/continents is evident, with a similar pattern of recommendations among developed as well as developing ones. No CPGs were found in Latin America as well as Oceania countries, where the incidence of HNC is high and limitations of access to treatment may be encountered.